Umeå universitets logga

umu.sePublikationer
Ändra sökning
Avgränsa sökresultatet
1 - 9 av 9
RefereraExporteraLänk till träfflistan
Permanent länk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Träffar per sida
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sortering
  • Standard (Relevans)
  • Författare A-Ö
  • Författare Ö-A
  • Titel A-Ö
  • Titel Ö-A
  • Publikationstyp A-Ö
  • Publikationstyp Ö-A
  • Äldst först
  • Nyast först
  • Skapad (Äldst först)
  • Skapad (Nyast först)
  • Senast uppdaterad (Äldst först)
  • Senast uppdaterad (Nyast först)
  • Disputationsdatum (tidigaste först)
  • Disputationsdatum (senaste först)
  • Standard (Relevans)
  • Författare A-Ö
  • Författare Ö-A
  • Titel A-Ö
  • Titel Ö-A
  • Publikationstyp A-Ö
  • Publikationstyp Ö-A
  • Äldst först
  • Nyast först
  • Skapad (Äldst först)
  • Skapad (Nyast först)
  • Senast uppdaterad (Äldst först)
  • Senast uppdaterad (Nyast först)
  • Disputationsdatum (tidigaste först)
  • Disputationsdatum (senaste först)
Markera
Maxantalet träffar du kan exportera från sökgränssnittet är 250. Vid större uttag använd dig av utsökningar.
  • 1.
    Bjursten, Henrik
    et al.
    Department of Cardiothoracic Surgery, Lund University, Skåne University Hospital, Lund, Sweden.
    Koul, Sasha
    Department of Cardiology, Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden.
    Pétursson, Pétur
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
    Odenstedt, Jacob
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
    Hagström, Henrik
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin. Heart Centre, Umeå University Hospital, Umeå, Sweden.
    Backes, Jenny
    Department of Cardiothoracic and Vascular Surgery, Örebro University Hospital, Örebro, Sweden.
    Nielsen, Niels Erik
    Department of Cardiology, Heart Centre, University Hospital, Linköping, Sweden.
    Rück, Andreas
    Department of Cardiology, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden.
    Johansson, Jan
    Department of Cardiology, Blekinge Hospital, Karlskrona, Sweden.
    James, Stefan
    Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
    Settergren, Magnus
    Department of Cardiology, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden.
    Götberg, Matthias
    Department of Cardiology, Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden.
    Yndigen, Troels
    Department of Cardiology, Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden.
    Characteristics and outcomes of patients receiving a second rescue valve during transcatheter aortic valve implantation2024Ingår i: Structural Heart, ISSN 2474-8706, Vol. 8, nr 2, artikel-id 100231Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Background: Transcatheter aortic valve implantation (TAVI) has become a safe procedure. However, complications occur, including uncommon complications such as valve malposition, which requires the implantation of an additional rescue valve (rescue-AV). The aim was to study the occurrence and outcomes of rescue-AV in a nationwide registry.

    Methods: The Swedish national TAVI registry was used as the primary data source, where all 6706 TAVI procedures from 2016 to 2021 were retrieved. Nontransfemoral access and planned valve-in-valve were excluded. In total, 79 patients were identified as having had a rescue-AV, and additional detailed data were collected for these patients. This dataset was analyzed for any characteristics that could predispose patients to a rescue-AV. The outcome of patients receiving rescue-AV also was studied.

    Results: Of the 5948 patients in the study, 1.3% had a rescue-AV. There were few differences between patients receiving 1 valve and rescue-AV patients. For patients receiving a rescue-AV, the 30-day mortality was 15.2% compared to 1.6% in the control group. A poor outcome after rescue-AV was often associated with a second complication; for example, stroke, need for emergency surgery, or heart failure. Among the patients with rescue-AV who survived at least 30 days, landmark analyses showed similar survival rates compared to the control group.

    Conclusions: Among TAVI patients in a nationwide register, rescue-AV occurred in 1.3% of patients. The 30-day mortality in patients receiving rescue-AV was high, but long-term outcome among 30-day survivors was similar to the control group.

    Ladda ner fulltext (pdf)
    fulltext
  • 2.
    Bollano, Entela
    et al.
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
    Redfors, Björn
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
    Rawshani, Araz
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
    Venetsanos, Dimitrios
    Department of Cardiology, and Department of Health, Medicine and Caring Sciences, Unit of Cardiovascular Sciences, Linköping University, Linköping, Sweden.
    Völz, Sebastian
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
    Angerås, Oskar
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
    Ljungman, Charlotta
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
    Alfredsson, Joakim
    Department of Cardiology, and Department of Health, Medicine and Caring Sciences, Unit of Cardiovascular Sciences, Linköping University, Linköping, Sweden.
    Jernberg, Tomas
    Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden.
    Råmunddal, Truls
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
    Petursson, Petur
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
    Smith, J. Gustav
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Cardiology, Clinical Sciences, Lund University, and Skåne University Hospital, Lund, Sweden; Wallenberg Center for Molecular Medicine and Lund University Diabetes Center, Lund University, Lund, Sweden.
    Braun, Oscar
    Department of Cardiology, Clinical Sciences, Lund University, and Skåne University Hospital, Lund, Sweden.
    Hagström, Henrik
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Avdelningen för medicin. Heart Centre, Umeå University Hospital, Umeå, Sweden.
    Fröbert, Ole
    Department of Cardiology, Faculty of Health, Örebro University, Örebro, Sweden.
    Erlinge, David
    Department of Cardiology, Clinical Sciences, Lund University, and Skåne University Hospital, Lund, Sweden.
    Omerovic, Elmir
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
    Temporal trends in characteristics and outcome of heart failure patients with and without significant coronary artery disease2022Ingår i: ESC Heart Failure, E-ISSN 2055-5822, Vol. 9, nr 3, s. 1812-1822Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Aims: Ischaemic coronary artery disease (CAD) remains the leading cause of mortality globally due to sudden death and heart failure (HF). Invasive coronary angiography (CAG) is the gold standard for evaluating the presence and severity of CAD. Our objective was to assess temporal trends in CAG utilization, patient characteristics, and prognosis in HF patients undergoing CAG at a national level.

    Methods and results: We used data from the Swedish Coronary Angiography and Angioplasty Registry. Data on all patients undergoing CAG for HF indication in Sweden between 2000 and 2018 were collected and analysed. Long-term survival was estimated with multivariable Cox proportional hazards regression adjusted for differences in patient characteristics. In total, 22 457 patients (73% men) with mean age 64.2 ± 11.3 years were included in the study. The patients were increasingly older with more comorbidities over time. The number of CAG specifically for HF indication increased by 5.5% per calendar year (P < 0.001). No such increase was seen for indications angina pectoris and ST-elevation myocardial infarction. A normal CAG or non-obstructive CAD was reported in 63.2% (HF-NCAD), and 36.8% had >50% diameter stenosis in one or more coronary arteries (HF-CAD). The median follow-up time was 3.6 years in HF-CAD and 5 years in HF-NCAD. Age and sex-adjusted survival improved linearly by 1.3% per calendar year in all patients. Compared with HF-NCAD, long-term mortality was higher in HF-CAD patients. The risk of death increased with the increasing severity of CAD. Compared with HF-NCAD, the risk estimate in patients with a single-vessel disease was higher [hazard ratio (HR) 1.3; 95% confidence interval (CI) 1.20–1.41; P < 0.001], a multivessel disease without the involvement of left main coronary artery (HR 1.72; 95% CI 1.58–1.88; P < 0.001), and with left main disease (HR 2.02; 95% CI 1.88–2.18; P < 0.001). The number of HF patients undergoing revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) increased by 7.5% (P < 0.001) per calendar year. The majority (53.4%) of HF-CAD patients were treated medically, while a minority (46.6%) were referred for revascularization with PCI or CABG. Compared with patients treated with PCI, the proportion of patients treated medically or with CABG decreased substantially (P < 0.001).

    Conclusions: Over 18 years, the number of patients with HF undergoing CAG has increased substantially. Expanded utilization of CAG increased the number of HF patients treated with percutaneous coronary intervention and coronary artery bypass surgery. Long-term survival improved in all HF patients despite a steady increase of elderly patients with comorbidities.

    Ladda ner fulltext (pdf)
    fulltext
  • 3.
    Hagström, Henrik
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Kardiologi. Heart Centre, Umeå University Hospital, Umeå, Sweden.
    Nyström Hagfors, Linda
    Umeå universitet, Samhällsvetenskapliga fakulteten, Institutionen för kost- och måltidsvetenskap.
    Tellström, Anna
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin. Clinical Research Center, Umeå University Hospital, Umeå, Sweden.
    Hedelin, Rikard
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin. Heart Centre, Umeå University Hospital, Umeå, Sweden.
    Lindmark, Krister
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin. Department of Clinical Sciences, Cardiology, Danderyd Hospital, Stockholm, Sweden.
    Low carbohydrate high fat-diet in real life assessed by diet history interviews2023Ingår i: Nutrition Journal, E-ISSN 1475-2891, Vol. 22, nr 1, artikel-id 14Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Background: Low carbohydrate high fat (LCHF) diet has been a popular low carbohydrate diet in Sweden for 15 years. Many people choose LCHF to lose weight or control diabetes, but there are concerns about the effect on long-term cardiovascular risks. There is little data on how a LCHF diet is composed in real-life. The aim of this study was to evaluate the dietary intake in a population with self-reported adherence to a LCHF diet.

    Methods: A cross-sectional study of 100 volunteers that considered themselves eating LCHF was conducted. Diet history interviews (DHIs) and physical activity monitoring for validation of the DHIs were performed.

    Results: The validation shows acceptable agreement of measured energy expenditure and reported energy intake. Median carbohydrate intake was 8.7 E% and 63% reported carbohydrate intake at potentially ketogenic levels. Median protein intake was 16.9 E%. The main source of energy was dietary fats (72.0 E%). Intake of saturated fat was 32 E% and cholesterol was 700 mg per day, both of which exceeded the recommended upper limits according to nutritional guidelines. Intake of dietary fiber was very low in our population. The use of dietary supplements was high, and it was more common to exceed the recommended upper limits of micronutrients than to have an intake below the lower limits.

    Conclusions: Our study indicates that in a well-motivated population, a diet with very low carbohydrate intake can be sustained over time and without apparent risk of deficiencies. High intake of saturated fats and cholesterol as well as low intake of dietary fiber remains a concern.

    Ladda ner fulltext (pdf)
    fulltext
  • 4.
    Louca, Antros
    et al.
    Department of Molecular and Clinical Medicine, Gothenburg University, Sweden; Department of Cardiology, Sahlgrenska University Hospital, Sweden.
    Alchay, Monér
    Department of Cardiology, Sahlgrenska University Hospital, Sweden.
    Råmunddal, Truls
    Department of Molecular and Clinical Medicine, Gothenburg University, Sweden; Department of Cardiology, Sahlgrenska University Hospital, Sweden.
    Rawshani, Araz
    Department of Molecular and Clinical Medicine, Gothenburg University, Sweden; Department of Cardiology, Sahlgrenska University Hospital, Sweden.
    Hagström, Henrik
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin. Heart Centre, Umeå University Hospital, Umeå, Sweden.
    Settergren, Magnus
    Department of Cardiology, Karolinska University Hospital and Karolinska Institute, Solna, Sweden.
    Nilsson, Konrad
    Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
    Shahim, Bahira
    Department of Cardiology, Karolinska University Hospital and Karolinska Institute, Solna, Sweden.
    James, Stefan
    Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
    Koul, Sasha
    Department of Clinical Sciences, Cardiology, Lund University Hospital, Lund, Sweden.
    Myredal, Anna
    Department of Molecular and Clinical Medicine, Gothenburg University, Sweden; Department of Cardiology, Sahlgrenska University Hospital, Sweden.
    Redfors, Björn
    Department of Molecular and Clinical Medicine, Gothenburg University, Sweden; Department of Cardiology, Sahlgrenska University Hospital, Sweden.
    Ioanes, Dan
    Department of Molecular and Clinical Medicine, Gothenburg University, Sweden; Department of Cardiology, Sahlgrenska University Hospital, Sweden.
    Völz, Sebastian
    Department of Molecular and Clinical Medicine, Gothenburg University, Sweden; Department of Cardiology, Sahlgrenska University Hospital, Sweden.
    Petursson, Petur
    Department of Molecular and Clinical Medicine, Gothenburg University, Sweden; Department of Cardiology, Sahlgrenska University Hospital, Sweden.
    Angerås, Oskar
    Department of Molecular and Clinical Medicine, Gothenburg University, Sweden; Department of Cardiology, Sahlgrenska University Hospital, Sweden.
    Coronary angiography following transcatheter aortic valve replacement: insights from the SWEDEHEART registry2024Ingår i: Catheterization and cardiovascular interventions, ISSN 1522-1946, E-ISSN 1522-726X, Vol. 104, nr 3, s. 570-582Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Background: Transcatheter aortic valve replacement (TAVR) is the most common treatment in patients with symptomatic severe aortic stenosis (AS). As concomitant coronary artery disease is common in AS patients, access to the coronary arteries following TAVR is of increasing importance.

    Objectives: This study evaluated the incidence and risk factors for unplanned coronary angiography following TAVR and, using fluoroscopic time as a surrogate, analyzed the complexity of coronary artery cannulation.

    Methods: All patients who underwent TAVR in Sweden between 2008 and 2022 were identified using the SWEDEHEART registry. The cumulative incidence of coronary angiography after TAVR was analyzed with mortality as a competing risk. Angiography and PCI complexity were analyzed using fluoroscopic time and compared across different transcatheter heart valve designs.

    Results: Out of 9806 patients, 566 subsequently required coronary angiography. The incidence was highest for three-vessel and/or left main disease. Younger age, the extent of prior coronary artery disease, and peripheral vascular disease were associated with an increased risk of coronary angiography. Fluoroscopy time was increased in TAVR patients compared to the control group with the longest fluoroscopy times observed in cases involving supra-annular and self-expanding valves.

    Conclusions: The incidence of coronary angiography following TAVR is still low. Younger patients and patients with concomitant coronary artery disease have a higher risk. Procedural time is longer in patients with a previous THV replacement. As TAVR is emerging as the first-line treatment in patients with longer life expectancy, facilitating coronary access is an important factor when considering which THV device to implant.

    Ladda ner fulltext (pdf)
    fulltext
  • 5.
    Nilsson, Konrad
    et al.
    Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
    James, Stefan
    Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
    Angerås, Oskar
    Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University, Gothenburg, Sweden; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
    Backes, Jenny
    Department of Cardiothoracic and Vascular Surgery, Örebro University Hospital, Sweden.
    Bjursten, Henrik
    Department of Cardiothoracic Surgery, Anaesthesia and Intensive Care, Lund University, Lund, Sweden; Department of Cardiothoracic Surgery, Lund University, Skåne University Hospital, Lund, Sweden.
    Candolfi, Pascal
    Nyon, Switzerland.
    Götberg, Mattias
    Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
    Hagström, Henrik
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin.
    Malmberg, Chiara
    IHE - The Swedish Institute for Health Economics, Stockholm, Sweden.
    Nielsen, Niels Erik
    Department of Cardiology, Heart Centre, University Hospital, Linköping, Sweden.
    Sarmah, Archita
    Nyon, Switzerland.
    Settergren, Magnus
    Heart and Vascular Unit, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
    Bromilow, Tom
    York Health Economics Consortium, University of York, York, United Kingdom.
    Cost-effectiveness analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at low risk of surgical mortality in Sweden2024Ingår i: Upsala Journal of Medical Sciences, ISSN 0300-9734, E-ISSN 2000-1967, Vol. 129, artikel-id e10741Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Background: Transcatheter aortic valve implantation (TAVI) has shown similar or improved clinical outcomes compared with surgical aortic valve replacement (SAVR) in patients with symptomatic severe aortic stenosis at low risk for surgical mortality. This cost-utility analysis compared TAVI with SAPIEN 3 versus SAVR in symptomatic severe aortic stenosis patients at low risk of surgical mortality from the perspective of the Swedish healthcare system.

    Methods: A published, two-stage, Markov-based cost-utility model that captured clinical outcomes from the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated according to Recommended Therapies (SWEDEHEART) registry (2018-2020) was adapted from the perspective of the Swedish healthcare system using local general population mortality, utility and costs data. The model had a lifetime horizon. Model outputs included changes in direct healthcare costs and health-related quality of life from using TAVI as compared with SAVR.

    Results: TAVI with SAPIEN 3 resulted in lifetime costs per patient of 940,541 Swedish krona (SEK) and lifetime quality-adjusted life years (QALYs) per patient of 7.16, whilst SAVR resulted in lifetime costs and QALYs per patient of 821,380 SEK and 6.81 QALYs, respectively. Compared with SAVR, TAVI offered an incremental improvement of +0.35 QALY per patient at an increased cost of +119,161 SEK per patient over a lifetime horizon, resulting in an incremental cost-effectiveness ratio of 343,918 SEK per QALY gained.

    Conclusion: TAVI with SAPIEN 3 is a cost-effective option versus SAVR for patients with symptomatic severe aortic stenosis at low risk for surgical mortality treated in the Swedish healthcare setting. These findings may inform policy decisions in Sweden for the management of this patient group.

    Ladda ner fulltext (pdf)
    fulltext
  • 6.
    Nilsson, Konrad
    et al.
    Department of Medical Sciences, Cardiology, Uppsala Universitet, Uppsala, Sweden; Department of Medicine, Visby Lasarett, Visby, Sweden.
    Lindholm, Daniel
    Department of Medical Sciences, Epidemiology, Uppsala Universitet, Uppsala, Sweden; Department of Medicine, Norrtälje Hospital (TioHundra AB), Norrtälje, Sweden.
    Backes, Jenny
    Department of Medical Sciences, Örebro Universitet, Örebro, Sweden.
    Bjursten, Henrik
    Department of Cardiothoracic Surgery, Anaesthesia and Intensive Care, Lund University/Skåne University Hospital, Lund, Sweden.
    Hagström, Henrik
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin. Heart Centre, Umeå University Hospital, Umeå, Sweden.
    Lindbäck, Johan
    Uppsala Clinical Research Center, Uppsala, Sweden.
    Pétursson, Pétur
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
    Settergren, Magnus
    Department of Cardiology, Karolinska Institutet, Stockholm, Sweden.
    Sarno, Giovanna
    Department of Medical Sciences, Cardiology, Uppsala Universitet, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala, Sweden.
    James, Stefan
    Department of Medical Sciences, Cardiology, Uppsala Universitet, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala, Sweden.
    Regional assessment of availability for transcatheter aortic valve implantation in Sweden: a long-term observational study2024Ingår i: European Heart Journal - Quality of Care and Clinical Outcomes, ISSN 2058-5225, E-ISSN 2058-1742, Vol. 10, nr 7, s. 641-649Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Background: Transcatheter aortic valve implantation (TAVI) is an increasingly important treatment option for patients with severe aortic stenosis. Its best implementation is debated, as few centres with high volumes are associated with better outcomes, while centralization might lead to an inferior availability of treatment for patients living far away. The aim of this study was to investigate the implementation of TAVI in Sweden with a focus on regional differences in terms of availability, short-term mortality, and waiting times.

    Methods: All patients undergoing TAVI between 2008 and 2020 from the Swedish Transcatheter Cardiac Intervention Registry (SWENTRY) were included. SWENTRY was linked to the National Cause of Death Registry and to publicly available geospatial data from Statistics Sweden.

    Results: A total of 7280 patients were included. Over time, TAVI interventions increased markedly, while surgical aortic valve replacement (SAVR) remained constant. There were no statistically significant regional differences in incidence between counties with or without a local TAVI centre (P = 0.7) and no clustering tendencies around regions with a local TAVI centre (P = 0.99). Thirty-day mortality improved over time without evidence of regional differences. No regional differences in waiting time from decision to intervention were found for TAVI centre regions and non-TAVI centre regions (P = 0.7).

    Conclusion: This nationwide study indicated no regional differences in terms of availability, short-term mortality, or waiting times. An organization with a few specialized centres was found to be sufficient to provide national coverage of TAVI interventions. Graphical Abstract

    Ladda ner fulltext (pdf)
    fulltext
  • 7.
    Omerovic, Elmir
    et al.
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
    James, Stefan
    Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden.
    Erlinge, David
    Department of Cardiology, Lund University, Skåne University Hospital, Lund, Sweden.
    Hagström, Henrik
    Department of Cardiology, Umeå University Hospital, Umeå, Sweden.
    Venetsanos, Dimitrios
    Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
    Henareh, Loghman
    Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
    Ekenbäck, Christina
    Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden.
    Alfredsson, Joakim
    Department of Cardiology, Linköping University Hospital, Linköping, Sweden.
    Hambreus, Kristina
    Department of Cardiology, Falun Hospital, Falun, Sweden.
    Redfors, Björn
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
    Rationale and design of BROKEN-SWEDEHEART: a registry-based, randomized, parallel, open-label multicenter trial to test pharmacological treatments for broken heart (takotsubo) syndrome2023Ingår i: American Heart Journal, ISSN 0002-8703, E-ISSN 1097-6744, Vol. 257, s. 33-40Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Background: Takotsubo syndrome (TS) is a life-threatening acute heart failure syndrome without any evidence-based treatment options. No treatment for TS has been examined in a randomized trial.

    Study design and objectives: BROKEN-SWEDEHEART is a multicenter, randomized, open-label, registry-based 2 × 2 factorial clinical trial in patients with TS designed to test whether treatment with adenosine and dipyridamole accelerates cardiac recovery and improves clinical outcomes compared to standard care (study 1); and apixaban reduces the risk of thromboembolic events compared to no treatment with antithrombotic drugs (study 2). The trial will enroll 1,000 patients. Study 1 (adenosine hypothesis) will evaluate 2 coprimary end points: (1) wall motion score index at 48 to 96 hours (evaluated in the first 200 patients); and (2) the composite of death, cardiac arrest, need for mechanical assist device or heart failure hospitalization within 30 days or left ventricular ejection fraction <50% at 48 to 96 hours (evaluated in 1,000 patients). The primary end point in study 2 (apixaban hypothesis) is the composite of death or thromboembolic events within 30 days or the presence of intraventricular thrombus on echocardiography at 48 to 96 hours.

    Conclusions: BROKEN-SWEDEHEART will be the first prospective randomized multicenter trial in patients with TS. It is designed as 2 parallel studies to evaluate whether adenosine accelerates cardiac recovery and improves cardiac function in the acute phase and the efficacy of anticoagulation therapy for preventing thromboembolic complications in TS. If either of its component studies is successful, the trial will provide the first evidence-based treatment recommendation in TS.

    Clinical trials identifier: The trial has been approved by the Swedish Medicinal Product Agency and the Swedish Ethical Board and is registered at ClinicalTrials.gov (NCT04666454).

    Ladda ner fulltext (pdf)
    fulltext
  • 8. Paulander, Johan
    et al.
    Olsson, Henrik
    Umeå universitet, Medicinska fakulteten.
    Lemma, Hailemariam
    Getachew, Asefaw
    San Sebastian, Miguel
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Epidemiologi och folkhälsovetenskap.
    Knowledge, attitudes and practice about malaria in rural Tigray, Ethiopia2009Ingår i: Global Health Action, ISSN 1654-9716, E-ISSN 1654-9880, Vol. 2Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Objective: To assess the knowledge, attitude and practice (KAP) regarding malaria and their determinants in a rural population of northern Ethiopia.

    Methods: The study was conducted in the district of Samre Saharti, Tigray, northern Ethiopia. A structured questionnaire collecting socio-demographic and malaria-related KAP information was administered to the mothers from a representative sample of households.

    Results: A total of 1652 questionnaires were available for analysis. Most of the respondents (92.7%) were able to mention at least one symptom of malaria. Mosquito as a cause of malaria was recognized by nearly half of the respondents (48.8%). Most of the households had a bednet (85.9%). To have a literate person at home, to belong to the lowland stratum, to have received some type of health education and to own a radio were associated with the knowledge of malaria. A strong association remained between living in the lowland stratum, to own a radio and to live close to the health post and the use of ITN. Being a housewife, lack of health education and to live further than 60 minutes walking distance to the health post were related to a delay on treatment finding.

    Conclusion: This study has identified some aspects which the MCP might need to improve. The knowledge about malaria transmission should be strengthened. Promotion of literacy and participation in health education are vital components in terms of malaria knowledge and practice. Issues related to geographical location and accessibility to health post should be also carefully examined.

    Ladda ner fulltext (pdf)
    fulltext
  • 9.
    Petursson, Petur
    et al.
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
    Oštarijaš, Eduard
    University of Pécs Medical School, Pécs, Hungary.
    Redfors, Björn
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
    Råmunddal, Truls
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
    Angerås, Oskar
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
    Völz, Sebastian
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
    Rawshani, Araz
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
    Hambraeus, Kristina
    Department of Cardiology, Falun Hospital, Falun, Sweden.
    Koul, Sasha
    Department of Cardiology, Skåne University Hospital, Lund, Sweden.
    Alfredsson, Joakim
    Department of Cardiology, Linköping University Hospital, Linköping, Sweden.
    Hagström, Henrik
    Department of Cardiology, Umeå University Hospital, Umeå, Sweden.
    Loghman, Henareh
    Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
    Hofmann, Robin
    Department of Cardiology, Södra Hospital, Stockholm, Sweden.
    Fröbert, Ole
    Department of Cardiology, Örebro University Hospital, Örebro, Sweden.
    Jernberg, Tomas
    Department of Cardiology, Danderyd University Hospital, Stockholm, Sweden.
    James, Stefan
    Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden.
    Erlinge, David
    Department of Cardiology, Skåne University Hospital, Lund, Sweden.
    Omerovic, Elmir
    Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
    Effects of pharmacological interventions on mortality in patients with Takotsubo syndrome: a report from the SWEDEHEART registry2024Ingår i: ESC Heart Failure, E-ISSN 2055-5822, Vol. 11, nr 3, s. 1720-1729Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Aims: Takotsubo syndrome (TS) is a heart condition mimicking acute myocardial infarction. TS is characterized by a sudden weakening of the heart muscle, usually triggered by physical or emotional stress. In this study, we aimed to investigate the effect of pharmacological interventions on short- and long-term mortality in patients with TS.

    Methods and results: We analysed data from the SWEDEHEART (the Swedish Web System for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) registry, which included patients who underwent coronary angiography between 2009 and 2016. In total, we identified 1724 patients with TS among 228 263 individuals in the registry. The average age was 66 ± 14 years, and 77% were female. Nearly half of the TS patients (49.4%) presented with non-ST-elevation acute coronary syndrome, and a quarter (25.9%) presented with ST-elevation myocardial infarction. Most patients (79.1%) had non-obstructive coronary artery disease on angiography, while 11.7% had a single-vessel disease and 9.2% had a multivessel disease. All patients received at least one pharmacological intervention; most of them used beta-blockers (77.8% orally and 8.3% intravenously) or antiplatelet agents [aspirin (66.7%) and P2Y12 inhibitors (43.6%)]. According to the Kaplan–Meier estimator, the probability of all-cause mortality was 2.5% after 30 days and 16.6% after 6 years. The median follow-up time was 877 days. Intravenous use of inotropes and diuretics was associated with increased 30 day mortality in TS [hazard ratio (HR) = 9.92 (P < 0.001) and HR = 3.22 (P = 0.001), respectively], while angiotensin-converting enzyme inhibitors and statins were associated with decreased long-term mortality [HR = 0.60 (P = 0.025) and HR = 0.62 (P = 0.040), respectively]. Unfractionated and low-molecular-weight heparins were associated with reduced 30 day mortality [HR = 0.63 (P = 0.01)]. Angiotensin receptor blockers, oral anticoagulants, P2Y12 antagonists, aspirin, and beta-blockers did not statistically correlate with mortality.

    Conclusions: Our findings suggest that some medications commonly used to treat TS are associated with higher mortality, while others have lower mortality. These results could inform clinical decision-making and improve patient outcomes in TS. Further research is warranted to validate these findings and to identify optimal pharmacological interventions for patients with TS.

    Ladda ner fulltext (pdf)
    fulltext
1 - 9 av 9
RefereraExporteraLänk till träfflistan
Permanent länk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf